SCYNEXIS, Inc.
News
SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference
Globe Newswire JERSEY CITY, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...\n more…
SCYX Stock Earnings: SCYNEXIS Misses EPS, Misses Revenue for Q2 2024
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nSCYX stock results show that SCYNEXIS missed analyst estimates for earnings per share and missed on revenue for the second quarter of...\n more…
SCYNEXIS GAAP EPS of -$0.30 misses by $0.10
SeekingAlpha.com: All News SCYNEXIS (SCYX) reports Q2 GAAP EPS of -$0.30, missing estimates by $0.10.\n more…
SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Globe Newswire Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a $10 million development milestone payment to...\n more…
SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports
Globe Newswire Reiterating cash runway of > 2 yearsJERSEY CITY, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and...\n more…
SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Simply Wall St It's been a good week for SCYNEXIS, Inc. ( NASDAQ:SCYX ) shareholders, because the company has just released its latest...\n more…